Formycon Highlights Greater Focus On Biosimilars As Athos Deal Completes
Anticipated Profits From Biosimilar Candidates To Expand Future Development
Executive Summary
Formycon has completed its acquisition of Athos’ biosimilar candidates for Stelara and Lucentis, following the announcement of the deal in March.
You may also be interested in...
Formycon Concludes Successful Development Of Stelara Biosimilar Ahead Of Annual Results
Formycon has successfully concluded the development of its ustekinumab biosimilar FYB202, with regulatory submissions planned for Q3. It is just one of many biosimilar candidates which the German firm expects to soon start making significant revenue contributions.
Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals
The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.
Fresenius Kabi And Formycon Ally On Stelara Rival
Fresenius Kabi and Formycon have announced a global licensing deal for the FYB202 ustekinumab proposed biosimilar rival to Stelara. The deal comes as Formycon has revealed plans to raise further funds to funnel into research and development through a fresh share issue.